← FDA DRUG APPROVALS

FDA ANDA · ANDA201049

PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE

Sponsor: CHARTWELL RX

APPLICATION
ANDA201049
TYPE
ANDA
ORIGINAL APPROVAL
2013-01-04
LATEST ACTION
2020-02-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDEPrescription
GLIMEPIRIDE 4MG, PIOGLITAZONE HYDROCHLORIDE 30MG · TABLET · ORAL
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDEPrescription
GLIMEPIRIDE 2MG, PIOGLITAZONE HYDROCHLORIDE 30MG · TABLET · ORAL

Approval history

2020-02-24Labeling · Supplement 7 · standardAP
2020-02-24Labeling · Supplement 8 · standardAP
2015-07-23Labeling · Supplement 5 · standardAP
2015-07-23Labeling · Supplement 4 · standardAP
2015-06-02Labeling · Supplement 1 · standardAP
2013-01-04Not Applicable · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →